Fig 4.

Delayed-type hypersensitivity (DTH) assay data. DTH reactivity was identified in seven of 24 assessable patients. (A) The diameter of induration is shown at 24 and 48 hours for those seven patients, both before vaccine and at 12 weeks (post). (B) The change, from before vaccine to week 12, in induration diameter (maximum of 24 hours and 48 hours, subtracting maximum prevaccine value, averaged for all seven patients) is shown for reactions to the six melanoma helper peptides (6MHP) and to the standard recall antigens. (C) The association between DTH reactivity and proliferative responses is shown in peripheral-blood mononuclear cell (PBMC) and sentinel immunized node (SIN). (D) Associations between DTH reactivity and study group, disease status, and disease stage are presented based on the proportions of patients in each subgroup with DTH reactivity. The denominators for subgroups are as follows: overall (n = 24), group A (n = 10), group B (n = 8), group C (n = 6), measurable disease (Dz; n = 8), nonmeasurable disease (n = 16), stage IV (n = 14), and stage III (n = 10).